Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.40p -1.26% 31.35p 30.20p 32.50p - - - 12,637 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 41.6 4.3 59.0 0.5 143.47

Ekf Diagnostics Share Discussion Threads

Showing 1451 to 1475 of 1475 messages
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
DateSubjectAuthorDiscuss
12/4/2018
07:01
Thanks wan Interesting research
9degrees
11/4/2018
07:45
I was catching up on the supporting evidence for sTNFR1, and thought that some readers may also be interested. The following is interesting and not just because of the predictive accuracy of the test, but also the potential of test to dramatically reduce the number of patients required in clinical trials, and furthermore that the evidence also suggests that the TNF receptor could be a therapeutic target, which would mean the test could yield far greater use as a companion diagnostic in any resulting therapeutic application (and in clinical trials for such) - Published on: April 20, 2017 Joslin's New Test Finds Patients With Diabetes at High Risk of Kidney Failure “Remarkably, when we use the TNF receptor to analyze risk of ESRD, the risk was almost identical for both type 1 and type 2 diabetes,” Krolewski said in a statement. “This implies that the etiologies are similar. This is a very important observation because in the medical community, the impression is that the progression of ESRD in type 1 is somehow different from type 2. As a result, many clinical trials do not include patients with type 1.” Also, he said, it could mean that the TNF receptor is a therapeutic target. Finding better ways to identify and treat those at risk of ESRD would save millions if more patients could avoid dialysis. The cost of ESRD is so high—dialysis centers bill commercial insurers up to $200,000 a year per patient—that these patients occupy a special category of Medicaid, since so few could pay for care on their own. Because the test more accurately pinpoints who is at risk of ESRD, Krolewski said it could be used to dramatically reduce the number of patients needed for clinical trials. “If our criterion is used in the recruitment of patients, you will not need 2000 to 3000 patients for a clinical trial; you will only need 400 patients.” Full article - https://tinyurl.com/test-accuracy-of-TNFR1 Further validation - January 2018 Validating the association between plasma tumour necrosis factor receptor 1 levels and the presence of renal injury and functional decline in patients with Type 2 diabetes. Author information 1 Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical Research, School of Medicine, University College, Dublin, Ireland. 2 Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland. 3 Clinical Chemistry, St. Vincent's University Hospital, Dublin, Ireland. 4 Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical Research, School of Medicine, University College, Dublin, Ireland; Department of Gastrosurgical Research & Education, Sahlgrenska Academy, University of Gothenburg, Sweden; Investigative Science, Imperial College London, United Kingdom. 5 Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical Research, School of Medicine, University College, Dublin, Ireland; Department of Gastrosurgical Research & Education, Sahlgrenska Academy, University of Gothenburg, Sweden. Electronic address: neil.docherty@ucd.ie. Abstract AIMS: Elevated plasma soluble tumour necrosis factor receptor 1 (TNFR1) predicts long-term progression of chronic kidney disease. We investigated the association between elevated TNFR1 and the presence of renal disease in patients with Type 2 diabetes mellitus registering a haemoglobin A1c (HbA1c) >48mmol/mol despite medical therapy. RESULTS: Upper quartile TNFR1 is independently associated with elevated urinary albumin-creatinine ratios, reductions in eGFR and strongly predicts the presence of stages 3-5 chronic kidney disease in regression modelling. Elevated TNFR1 levels are associated with increased plasma C-reactive protein and augmented leptin-adiponectin ratio. CONCLUSIONS: Our study confirms plasma TNFR1 as a surrogate of renal structural and functional impairment in patients with type 2 diabetes mellitus. Association of TNFR1 with markers of systemic inflammation and adipose stress indicates that TNFR1 may be a biomarker of these processes as components of the pathogenesis of diabetic kidney disease. Link - https://tinyurl.com/Validation-of-TNFR1
wan
09/4/2018
09:43
Fwiw, I think we will get to know more about the commercial strategy in the US once the Quo-Test products are approved (which I am expecting). Given the size of the commercial opportunity in the US that the combined approvals will enable, it will, in my opinion, have 'already' drawn strong interest from potential distribution partners.
wan
09/4/2018
09:28
N+1 Singer analyst Chris Glasper has published commentary today in which he described news from EKF of FDA 510k approval and CLIA Waiver as “very positive news” and asserts that “the potential opportunity is material for EKF”, with a “$35m+ market for point of care testing in the US to go at”. Forecasts remain unchanged at the moment but he writes: “We make no changes to our estimates, pending confirmation of the commercial strategy, which we expect in the coming months. We continue to see meaningful upside to the current share price on this and other opportunities in the pipeline.” N+1 Singer currently forecast £43.4m revenue for 2018, adj EBITDA of £10m and £7.5m adj PBT. For 2019 these rise to £44.7m, adj EBITDA of £10.8m and adj PBT of £8.0m. (END) Indeed I concur ;-) I also see material upside.
wan
09/4/2018
09:27
been accumulating here over the last week. strong cash flow good balance sheet and top quality products with strong market position. todays news should add to the positive share price advance aimho. woody
woodcutter
09/4/2018
07:25
With today's announcement of the US Food and Drug Administration approval of EKF's DiaSpect Tm, for use in point of care and Certificate of Waiver settings, we have an excellent start to the first half, but I don't think the good news will stop here! From the FY Results - Outlook We are looking forward to finalising our two FDA applications in the first half of 2018, and to update on progress with our sTNFR project. At the same time, we anticipate receiving completed registrations for Beta Hydroxybutyrate (β-HB) in Mexico, Brazil and Colombia as well as the Indian registration of DiaSpect Tm all in the first half of 2018. (END) These registrations/approvals, if achieved, will have a material and positive impact on revenues going forwards!
wan
04/4/2018
15:48
I would add that managing chronic Kidney Disease (CKD)/End Stage Renal Disease (ESRD) via new technology/techniques could potentially provide big reward and importantly a step change in social care/patient benefit. A focus on prevention and management could help to reduce the number of cases and therefore the treatment costs associated with CKD and ESRD. For example, the staggering annual medical costs in the US have been estimated at over $98 billion (yes apparently that's the correct estimate!) for Medicare beneficiaries.
wan
04/4/2018
15:27
An interesting price breakout today on no new news! I can see some news flow regarding managing End Stage Renal Disease via artificial intelligence, but nothing specifically relating to EKF yet.
wan
21/3/2018
12:25
Mac/ Wan: the various medical implications wan has been putting through have been helpful background for the ordinary person to try to understand what is possible for future expansion. The spin off details are still not in place but progressing,nothing definite or in place yet. Clinical trials taking place in USA, aim is to achieve sales expansion there, S.America and China. Building on existing growth of streamlined group and further capital expenditure in Germany. Nice to hear and see persons managing company.My comment to wan earlier appears to have moved the shares by the market makers ?
ingroid
21/3/2018
11:16
Ingroid, Is it possible to share your valuable insight with the rest of us, fellow shareholders? Thanks Mac.
macarona
21/3/2018
09:02
Thanks Ingroid. I was invited, but I was unable to attend the EKF meeting. I would very pleased to receive any interesting material etc. Perhaps you could highlight the material/details via a personal ADVFN message?
wan
21/3/2018
08:23
Great article wan.went to the open analyst /shareholder meeting late Thursday afternoon. Very enlightening . May have interesting material and facts from it for you to digest if there is another way for contact.
ingroid
18/3/2018
06:34
Renalytix AI PLC was incorporated in the UK on 15 March 2018. (AI = Artificial Intelligence) Share capital - 50,000 shares at £1 each EKF Diagnostics own all the shares. RENALYTIX AI PLC - Overview (free company information from Companies House) https://beta.companieshouse.gov.uk/company/11257655 6 Directors are listed, five associated to EKF, and if my initial investigation and subsequent findings are correct, the 6th director, James McCullough, gives us some insight as to how things might pan out. James McCullough was the founder and CEO of Exosome Diagnostics, he is now a managing partner at Renwick Capital (scroll further down and readers will also note David Evans, ex BBI, IDS ect) - James McCullough James has leadership experience building emerging technology companies in both public and private sectors with specific expertise in the life-sciences industry. His skills include equity and debt capital formation, strategic development and partnerships, executive team structuring, regulatory issues and marketing. James was most recently Chief Executive Officer of Exosome Diagnostics, a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer. https://tinyurl.com/Renwick-Team I note that Renwick highlight the following recent news article from the Wall Street Journal - When Jim Breyer invested in Facebook in 2005, he never expected social networking to be where it is today. Now he’s betting the intersection of artificial intelligence and medicine is poised for its own big breakout. Mr. Breyer and his firm, Breyer Capital, are leading a $25 million Series A round for Paige.AI , a startup applying AI to pathology to improve diagnosis and treatment of cancer. “Over the next decade there will be several companies in the fields of artificial intelligence and medicine that will provide enormous investment returns and at the same time make fundamental differences in patients’ and doctors’ lives,” Mr. Breyer said. full news item - https://tinyurl.com/AI-and-Medicine So it would appear that EKF's soluble tumor necrosis factor receptor 1 has great potential, and perhaps potential beyond the initial indication of End Stage Renal Disease, as elevations in circulating soluble tumor necrosis factor receptor 1 (sTNFR1) has been reported in a wide variety of clinical conditions including cancer, congestive heart failure, rheumatoid arthritis, neurological diseases and infection. Looking forward to further news on the new venture!
wan
16/3/2018
07:30
EKF has put the Times article on their news page - RenalytixAI (An EKF Diagnostics subsidiary) is raising funds to develop AI for tracking kidney disease RenalytixAI, an EKF Diagnostics (EKF) subsidiary company, is raising $25m (£17.6m) to float one of its divisions in America and then use the funds to develop artificial intelligence for tracking kidney disease. Cardiff-based EKF Diagnostics, which makes medical devices to monitor blood glucose levels and hemoglobin analyzers, hopes the new company (RenalytixAI) can help it secure deals with big hospital groups across the US. Full story - hxxps://www.ekfdiagnostics.com/renalytixai-an-ekf-diagnostics-subsidiary-is-raising-funds-to-develop-ai-for-tracking-kidney-disease.html
wan
14/3/2018
08:00
Another good set of Results with net cash improving further, despite making a number of investments in the business and with borrowings reduced significantly to £1.2m. The sTNFR venture now talks about numerous partners, which is an interesting development.
wan
29/1/2018
07:29
I don't think it will work like that, hence no announcement today! It will be a new entity listed in the US, so for me it's about how much the assets/technology has been valued at, and how much of the new entity will EKF own.
wan
28/1/2018
12:50
Agreed - Will need an announcement on Monday but the Times article makes no mention of a partner and only "hopes the new company can help it secure deals" - the way it reads is as though it is a straight fund raise - If so at what discount? Roll on Monday !!
pugugly
28/1/2018
11:51
Perhaps they gave the Times the scoop late Friday or yesterday, so if they announce Monday no harm done. The sTNFR biomarker technology has a carrying value of nil, so very interested to see what EKF's share of the new entity is. It will also be interesting to see who the partner is. That aside, listing in the US is quite exciting as the US appears to better appreciate healthcare/technology and thus apply good values.
wan
28/1/2018
10:04
Looks like a massive data leak before any notification to market or existing shareholders - A google seach for RenalyxAI only finds today's Times Article - No market notification that I can find anywhere of a $25M fundraising - unless this has been (as usual) a concealed placing with Institutions and insiders - If so usual stink - Also last announcement to market appears to indicate a joint venture "The Directors intend to establish a joint venture to develop sTNFR as a routine test for predicting the progression of diabetic patients to ESRD and will make further announcements at the appropriate time" Unless the directors consider that this announcement on 11th Jan is a get out clause.
pugugly
28/1/2018
06:55
In their most recent Trading Update, EKF stated their intentions to spin-out its sTNFR biomarker technology into a separate entity. According to the Sunday Times, EKF is going to float one of its divisions in America - Sabah Meddings January 28 2018 Welsh boffins at EKF use AI for kidney disease https://tinyurl.com/EKF-US-Float In the Trading Update they also stated; "The Directors intend to establish a joint venture to develop sTNFR as a routine test for predicting the progression of diabetic patients to ESRD and will make further announcements at the appropriate time." I assume we are due further announcements!
wan
18/1/2018
18:03
Yes sell on news and buy into dip this has a lot going for it .
sirshagalot
11/1/2018
07:23
Another solid trading update today confirming a very healthy 2017, and a healthy increase in the net cash position to £6.8m. sTNFR spin-out offers interesting upside considering it is valued at nil! That aside I think we will see some good growth opportunities realised during 2018.
wan
07/11/2017
07:38
Some large volumes of late, so I assume we will see RNS's accordingly. I am confident that EKF will deliver on their outlook in terms of sales growth. Over the medium term, the following could see a big uplift in revenues from the US - "Medium-term growth opportunities from new registrations and customers: – Draft agreements in place with OEM partners in USA for DiaSpect Tm and Quo-Test A1c" New EKF product introduction at Medica (next week) - Article by CHRIS MIDDLETON 06/11/2017 Cardiff-based EDK Diagnostics is set to introduce a new product at Medica – “POC Connect” – a data management mobile app that enables the storage, access and transmission of haemoglobin results directly from EFK Diagnostic’s DiaSpect Tm haemoglobin analyzer to a smartphone via Bluetooth® technology. The POC Connect mobile app is the world’s first mobile data management solution for a reagent-free haemoglobin testing device. POC Connect is ideal for mobile health checks and anaemia screening in countries where environmental conditions may be challenging or where there may not be consistent internet availability. Katja Lemburg, Hematology Global Product Manager from EKF Diagnostics said, “Within developing countries, there is a growing demand for mobile data management solutions due to the lack of internet-based communications infrastructure and the by-passing of more traditional based middleware providers. “So this new development is an ideal solution where internet connections can be unreliable. Mobile health care services are on the increase so we hope to see our smartphone-based connectivity solution playing a part in this growing trend. “We’re looking forward to unveiling this world first at Medica this year.” Full article - https://tinyurl.com/product-introduction
wan
05/11/2017
07:35
An excellent article - Diagnosing Diabetes: The Value of HbA1c Testing ARTICLE Nov 03, 2017 | By Anna MacDonald, Editor for Technology Networks We spoke to EKF’s Gavin Jones to learn more about the current methods of diabetes diagnosis and monitoring, the advantages of HbA1C testing, and how testing may change in the future. Where do you see the future of diabetes diagnostics headed? There are a number of improvements in the use of HbA1c for the monitoring of diabetes currently being considered, recently CAP (College of American Pathologists) and NGSP (National Glycohemoglobin Standardization Program) agreed that they should tighten the criteria for the HbA1c survey to ±5% beginning in 2019. Currently the requirement is to meet ±6% to the reference method, this change will undoubtedly reduce the number of available HbA1c methods on the market and improve the quality of results of those that remain, leading to a more controlled and consistent testing environment. Whilst seen by some manufacturers as a challenging criteria to meet, this change can only be looked upon as a positive improvement to the accuracy and precision of HbA1c monitoring on an industry-wide scale. Point-of-care testing As POC HbA1c testing becomes more accepted, it will start to become a more viable option for the diagnosis of diabetes. There are already POC HbA1c methods that meet the same criteria for diagnosis as lab systems, and with the increased accuracy being imposed upon the industry, the argument for only allowing lab systems to be used for diagnosis is slipping away. The benefits of POC HbA1c measurement, both clinically and from a patient-engagement perspective, cannot be ignored. It is only a matter of time before this becomes the accepted method for diabetes diagnosis. Full story (a very worthwhile read) - https://tinyurl.com/point-of-care-testing
wan
02/11/2017
16:36
2nd November 2017 EKF Diagnostics, the global in vitro diagnostics company, announces that its Stanbio Chemistry Procalcitonin (PCT) LiquiColor® assay has been FDA cleared and validated for use on Beckman AU 480, 680 and 5800 clinical chemistry analyzers. EKF is pleased to confirm the immediate availability of a user defined application (UDA) for running this 10 minute test for bacterial infection and sepsis on these Beckman AU analyzers. https://tinyurl.com/EKF-Procalcitonin-Assay
wan
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180422 06:54:32